NCT00887627

Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild & Moderate Kidney Function Impairment to Subjects With Normal Kidney Function

A Phase 1, Open-Label Study to Assess the Effects of Renal Impairment on the Pharmacokinetics of Intravenous Conivaptan

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Cumberland Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

A study to compare a conivaptan PK in subjects with mild or moderate kidney function impairment to subjects with normal kidney function after a 48-hour continuous infusion of conivaptan.

Conditions

• Kidney Diseases
• Hyponatremia

Interventions

Type	Name	Description
DRUG	conivaptan hydrochloride	intravenous

Timeline

• Start date: 2009-04-01
• Primary completion: 2010-07-01
• Completion: 2010-07-01
• First posted: 2009-04-24
• Last updated: 2014-05-02

Locations

1 site across 1 country: United States